|  |  |  |  |
| --- | --- | --- | --- |
| **Criteria Title** | Endocrine-Metabolic Analog | | |
| **Criteria Subtitle** | Sandostatin (octreotide) | | |
| **Approval Level** | GCNSeqNo | | |
| **Products**   |  |  | | --- | --- | | Preferred |  | | Non-Preferred |  | | Brand |  | | Generic |  | | Other |  | | Drug Name | Corresponding Code(s) | Type of Code (GCNSeqNo, HICL, NDC) |
| SANDOSTATIN | 006584 | GCNSeqNo |
| SANDOSTATIN | 006585 | GCNSeqNo |
| SANDOSTATIN | 006586 | GCNSeqNo |
| SANDOSTATIN | 016587 | GCNSeqNo |
| SANDOSTATIN | 016588 | GCNSeqNo |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sequence Number** | **Question ID** | **Default Next Question ID** | **Question Type** | **Question Text** | **Choice Text** | **Next Question ID** |
| 1 | 0998 |  | Select | Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)? | New Start (initial authorization request) | 0999 |
| Continuation (re-authorization request) | 2000 |
| 2 | 0999 |  | Select | Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? | Y | 1000 |
| N | 1235 |
| 3 | 1000 |  | Select | Is the medication being prescribed by or in consultation with an endocrinologist or oncologist? | Y | 1001 |
| N | 1235 |
| 4 | 1001 |  | Select and Free Text | Has the provider submitted documentation of the patient’s baseline IGF-I (somatomedin C) level above the normal range for the patient’s age?    If yes, please submit documentation. | Y | 1002 |
| N | 1235 |
| 5 | 1002 |  | Select and Free Text | Has the patient had an inadequate clinical response to surgery, radiation, or bromocriptine  mesylate?  If yes, please submit documentation. | Y | END (Pending Manual Review) |
| N | 1003 |
| 6 | 1003 |  | Select and Free Text | Is surgical resection not an option?  If yes, please submit documentation. | Y | END (Pending Manual Review) |
| N | 1235 |
| 7 | 2000 |  | Select and Free Text | Has the provider submitted documentation of clinical response?    Please note: IGF-I (somatomedin C) level should be re-evaluated at 180-day intervals).  If yes, please submit documentation. | Y | END (Pending Manual Review) |
| N | 1235 |
| 8 | 1235 |  | Free Text | Please provide the rationale for the medication being requested. | END (Pending Manual Review) | |

LENGTH OF AUTHORIZATIONS: Initial authorizations will be up to 90 days. Subsequent authorizations will be up to 365 days.

|  |  |
| --- | --- |
| **Last Approved** | 4/10/2023 |
| **Other** |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Criteria Title** | Endocrine-Metabolic Analog | | |
| **Criteria Subtitle** | Sandostatin LAR (Long-Acting Octreotide Formulation) | | |
| **Approval Level** | GCNSeqNo | | |
| **Products**   |  |  | | --- | --- | | Preferred |  | | Non-Preferred |  | | Brand |  | | Generic |  | | Other |  | | Drug Name | Corresponding Code(s) | Type of Code (GCNSeqNo, HICL, NDC) |
| SANDOSTATIN LAR | 041347 | GCNSeqNo |
| SANDOSTATIN LAR | 041348 | GCNSeqNo |
| SANDOSTATIN LAR | 041349 | GCNSeqNo |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sequence Number** | **Question ID** | **Default Next Question ID** | **Question Type** | **Question Text** | **Choice Text** | **Next Question ID** |
| 1 | 0998 |  | Select | Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)? | New Start (initial authorization request) | 0999 |
| Continuation (re-authorization request) | 2000 |
| 2 | 0999 |  | Select | Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? | Y | 1000 |
| N | 1235 |
| 3 | 1000 |  | Select | Is the medication being prescribed by or in consultation with an endocrinologist or oncologist? | Y | 1001 |
| N | 1235 |
| 4 | 1001 |  | Select and Free Text | Has the patient been previously treated with short-acting injection for at least 14 days with documented success?    If yes, please submit documentation. | Y | END (Pending Manual Review) |
| N | 1235 |
| 5 | 2000 |  | Select and Free Text | Has the provider submitted documentation of clinical response?    If yes, please submit documentation. | Y | END (Pending Manual Review) |
| N | 1235 |
| 6 | 1235 |  | Free Text | Please provide the rationale for the medication being requested. | END (Pending Manual Review) | |

LENGTH OF AUTHORIZATIONS: Initial authorizations will be for 180 days. Subsequent authorizations will be up to 365 days.

|  |  |
| --- | --- |
| **Last Approved** | 4/10/2023 |
| **Other** |  |